Vivos Therapeutics (VVOS) Equity Average (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Equity Average data on file, last reported at -$1.3 million in Q1 2026.

• Quarterly Equity Average fell 121.75% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 121.75% YoY) and the FY2025 annual result came in at $3.2 million, down 23.44% from the prior year.
• Equity Average declined to -$1.3 million in Q1 2026 per VVOS's latest filing, from $491000.0 in the prior quarter.
• Across five years, Equity Average topped out at $23.3 million in Q1 2022 and bottomed at -$1.3 million in Q1 2026.
• The 5-year median for Equity Average is $4.5 million (2023), against an average of $6.2 million.
• The widest annual swing landed in 2024, when Equity Average surged 3317.72%; it then plunged 121.75% in 2026.
• Tracing VVOS's Equity Average over 5 years: stood at $7.3 million in 2022, then tumbled by 96.88% to $228500.0 in 2023, then surged by 3317.72% to $7.8 million in 2024, then sank by 93.71% to $491000.0 in 2025, then sank by 373.73% to -$1.3 million in 2026.
• Per Business Quant, the three latest VVOS Equity Average figures stand at -$1.3 million (Q1 2026), $491000.0 (Q4 2025), and $3.6 million (Q3 2025).

Peer Comparison